---

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Transaction Summary

• Completed a $100M IPO in 2014
• Lead product, abicipar, started pivotal Phase III clinical trials for AMD - leading cause of blindness

• Zurich-Schlieren, Switzerland
• SIX: MOLN


• Contact:
  Petri Vainio
  
• www.molecularpartners.com
• IPO

Related News

• Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized
• Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and
• Molecular Partners’ Strategic Partner Allergan Announced Today that EMA has Validated the Marketing
• Molecular Partners and Amgen Announce Strategic Collaboration in Immuno-Oncology